CYP450 and drug efflux transporters polymorphism influence clinical outcomes of Thai osimertinib-treated non-small cell lung cancer patients

Background: Osimertinib has shown greater efficacy than standard epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and fewer grade 3 or higher adverse drug reactions (ADRs) in patients with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Teerapat Majam, Chonlaphat Sukasem, Thanyanan Reungwetwattana, Phichai Chansriwong, Chalirmporn Atasilp, Narumol Trachu, Thanaporn Thamrongjirapat, Rattanaporn Sukprasong, Jennis Meanwatthana
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2023-11-01
Serija:	Frontiers in Pharmacology
Teme:	non-small cell lung cancer pharmacogenetics single nucleotide polymorphisms (SNPs) osimertinib drug-metabolizing enzymes transporters
Online dostop:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1222435/full
Oznake:	Označite Brez oznak, prvi označite!